Merus Stock Price, News & Analysis

Merus N.V. (MRUS) has announced the upcoming presentation of a poster discussing the mechanism and effectiveness of its drug MCLA-129 at the AACR Annual Meeting 2022 on April 10. MCLA-129 targets EGFR and c-MET, critical in treating non-small cell lung cancer (NSCLC). Currently, MCLA-129 is in a phase 1/2 clinical trial aimed at assessing safety, tolerability, and clinical activity in patients with advanced tumors. Merus has a collaboration with Betta Pharmaceuticals for its development in China while retaining global rights outside the region.

Merus N.V. (Nasdaq: MRUS) reported financial results for 2021, revealing a net loss of $66.8 million.

Collaboration revenue increased to $49.1 million, up from $29.9 million in 2020, driven by substantial contributions from Lilly and Incyte. Research and development expenses rose to $98.2 million, reflecting higher costs related to zenocutuzumab (Zeno) and MCLA-129. The company ended the year with cash, cash equivalents, and marketable securities of $430.7 million, projected to sustain operations beyond 2024. Clinical updates for Zeno, petosemtamab, and MCLA-129 are expected in 2022.

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in several upcoming investor conferences. These include the Guggenheim Healthcare Talks/2022 Oncology Conference on February 10, the Citi 2022 Virtual Immuno-Oncology Summit on February 16, and the 11th Annual SVB Leerink Global Healthcare Conference on February 17. Webcasts of these events will be available on the Company's Investors page, with archived presentations accessible for a limited time.

Merus N.V. (Nasdaq: MRUS) has appointed Shannon Campbell as the Executive Vice President & Chief Commercial Officer, effective February. With over 25 years of experience in pharmaceuticals, Campbell aims to enhance Merus's commercial strategy for its lead candidate, zenocutuzumab, and its pipeline of innovative antibodies. Additionally, Merus has regained global rights to MCLA-145 following Incyte's decision to opt-out of ex-U.S. development, providing an opportunity to advance this candidate in solid tumors.

Merus N.V. (Nasdaq: MRUS) has presented positive clinical data for zenocutuzumab (Zeno) in combination with trastuzumab and vinorelbine, targeting HER2+ metastatic breast cancer (MBC) at the San Antonio Breast Cancer Symposium. The triplet combination met its primary endpoint with a clinical benefit rate (CBR) of 49% after 24 weeks. This combination demonstrates meaningful activity in patients who have undergone extensive prior therapies. Despite positive results, Merus does not plan to advance to a phase 3 trial for MBC without a partner but will focus on other indications.

Merus N.V. (Nasdaq: MRUS) presented clinical data on MCLA-145 at the virtual ESMO Immuno-Oncology Congress 2021. The phase 1 trial, involving 34 patients with solid tumors, showed preliminary evidence of antitumor activity, especially at doses ≥25 mg biweekly. Patients were treated at eight dose levels with a median age of 60.5 years. While treatment-related adverse events occurred in 67.6% of patients, robust T-cell activation was recorded. The trial aims to refine the maximum tolerated dose and evaluate efficacy in PD-L1+ tumors.

Merus N.V. (MRUS) announced interim data from the phase 1/2 trial of its bispecific antibody MCLA-145, targeting CD137 and PD-L1 in solid tumors, as of July 14, 2021. This data will be presented at the ESMO Immuno-Oncology Congress 2021 from December 8-11, 2021. The ongoing trial includes a dose escalation phase followed by planned expansion, marking MCLA-145 as a key candidate co-developed with Incyte. Merus retains commercialization rights in the U.S. and aims to leverage its innovative Bispecific platform for enhanced cancer treatment.

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, has announced that CEO Bill Lundberg, M.D., will participate in a fireside chat at the Jefferies London Healthcare Conference. This virtual event is scheduled for November 18, 2021, and the prerecorded session will be available on the Company's investor webpage at 8:00 am GMT/3:00 am ET. Merus is known for developing innovative multispecific antibody therapeutics, Biclonics and Triclonics, which show potential advantages similar to conventional human monoclonal antibodies.

Merus N.V. (Nasdaq: MRUS) announced the pricing of a public offering of 3,859,650 common shares at $28.50 per share, generating approximately $110.0 million in gross proceeds. The offering, set to close on or about November 9, 2021, includes an option for underwriters to purchase an additional 578,947 shares. The funds will be utilized for advancing clinical development, preclinical research, and general corporate purposes. Jefferies LLC and SVB Leerink LLC are the joint book-running managers for the offering.